(Q43452461)

English

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

scientific article published in December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

author name string

GlaxoSmithKline Vaccine HPV-007 Study Group

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

B Romanowski

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

P Colares de Borba

3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

P S Naud

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

C M Roteli-Martins

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

N S De Carvalho

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

J C Teixeira

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

F Aoki

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

B Ramjattan

9

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

R M Shier

10

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

R Somani

11

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

S Barbier

12

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

M M Blatter

13

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

C Chambers

14

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

D Ferris

15

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

S A Gall

16

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

F A Guerra

17

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

D M Harper

18

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

J A Hedrick

19

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

D C Henry

20

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

A P Korn

21

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

R Kroll

22

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

A-B Moscicki

23

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

W D Rosenfeld

24

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

B J Sullivan

25

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

C S Thoming

26

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

S K Tyring

27

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

C M Wheeler

28

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

G Dubin

29

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

A Schuind

30

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

T Zahaf

31

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Mary Greenacre

32

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

An Sgriobhadair

33

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

374

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

9706

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1975-1985

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Human papillomavirus and cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification of papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinician's guide to human papillomavirus immunology: knowns and unknowns

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961567-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)61567-1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43452461&oldid=1989086067"